Conversely, kallistatin gene therapy in MI animal models inhibits cardiac injury and remodeling, as well as hypertrophy by inhibiting oxidative stress and modulating the SIRT1/peroxisome proliferators-activated receptor α (PPARα) pathway (45). Here, SERPINA4 is linked to myocardial infarction.